세계의 단백질 치료제 시장 규모 조사 및 예측 : 제품별, 용도별, 지역별 분석(2023-2030년)

Global Protein Therapeutics Market is valued at approximately USD 325.35 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.1% over the forecast period 2023-2030. Protein therapeutics refers to a class of therapeutic agents that are based on proteins or peptides. Proteins are substantial molecules that are crucial for a variety of biological functions, such as immune function, metabolism, and cell signaling. These therapeutic compounds are intended to treat illnesses, disorders, or medical conditions by interacting with certain bodily targets, such as receptors, enzymes, or signaling molecules. The favorable regulatory environment, increase in the geriatric population, and development of the biologics sector, coupled with the rise in healthcare expenditure are the key factors that are spurring the market demand across the globe.

Additionally, the rising prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and autoimmune diseases is propelling the demand for protein therapeutics during the estimated period. According to National Cancer Institute, in 2018, the number of cancer patients is estimated to account for 18.1 million, which is projected to reach 29.5 million patients by the year 2040. Moreover, the International Diabetic Federation (IDF) reported that in 2021 approximately 537 million adults (20-79 years) are living with diabetes. Also, the total number of people living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Thus, these conditions generally require targeted and personalized treatment approaches like protein therapeutics, which, in turn, augment the market growth at a considerable rate. Furthermore, the rising advancements in biotechnology and protein engineering, as well as the growth in proteomic research present various lucrative opportunities over the forecasting years. However, the high production costs required and the complex manufacturing processes are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Protein Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing advancements in biotechnology, growing funding for research and development activities, along with the presence of key players in the region. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecasting years. The rapidly growing geriatric population, increasing patient awareness toward protein therapeutics, as well as rising prevalence of chronic diseases are significantly propelling the market demand across the region.

Major market players included in this report are:

• Novo Nordisk AS
• Baxter International Inc.
• Amgen Inc.
• Merck and Co., Inc.
• Sanofi S.A.
• Eli Lilly And Company
• Abbott Laboratories
• Pfizer Inc.
• Johnson and Johnson (Janssen Pharmaceuticals)
• F. Hoffmann La Roche Ltd

Recent Developments in the Market:

• In December 2022, Enlaza Therapeutics announced the introduction with USD 61 million in financing with the objective of advancing the company's first covalent biologic therapeutic platform. The company integrated novel innovations that allow the introduction of proprietary unnatural amino acids to protein drugs, which allows specific covalent binding to their target proteins.

Global Protein Therapeutics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, Application, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
• Human Growth Hormone
• Follicle Stimulating Hormone

By Application:

• Metabolic Disorders
• Immunologic Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

By Region:

• North America
• U.S.
• Canada

• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

• Latin America
• Brazil
• Mexico

• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Protein Therapeutics Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Protein Therapeutics Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Protein Therapeutics Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Protein Therapeutics Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Protein Therapeutics Market Dynamics

• 3.1. Protein Therapeutics Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Development of the biologics sector
    • 3.1.1.2. Rising prevalence of chronic diseases
  • 3.1.2. Market Challenges
    • 3.1.2.1. High production costs required
    • 3.1.2.2. Complex manufacturing processes
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising advancements in biotechnology and protein engineering
    • 3.1.3.2. Growth in proteomic research

Chapter 4. Global Protein Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Protein Therapeutics Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Protein Therapeutics Market by Product, Performance - Potential Analysis
• 5.3. Global Protein Therapeutics Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Protein Therapeutics Market, Sub Segment Analysis
  • 5.4.1. Monoclonal Antibodies
  • 5.4.2. Insulin
  • 5.4.3. Fusion Protein
  • 5.4.4. Erythropoietin
  • 5.4.5. Interferon
  • 5.4.6. Human Growth Hormone
  • 5.4.7. Follicle Stimulating Hormone

Chapter 6. Global Protein Therapeutics Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Protein Therapeutics Market by Application, Performance - Potential Analysis
• 6.3. Global Protein Therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Protein Therapeutics Market, Sub Segment Analysis
  • 6.4.1. Metabolic Disorders
  • 6.4.2. Immunologic Disorders
  • 6.4.3. Cancer
  • 6.4.4. Hormonal Disorders
  • 6.4.5. Genetic Disorders
  • 6.4.6. Others

Chapter 7. Global Protein Therapeutics Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Protein Therapeutics Market, Regional Market Snapshot
• 7.4. North America Protein Therapeutics Market
  • 7.4.1. U.S. Protein Therapeutics Market
    • 7.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Application breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Protein Therapeutics Market
• 7.5. Europe Protein Therapeutics Market Snapshot
  • 7.5.1. U.K. Protein Therapeutics Market
  • 7.5.2. Germany Protein Therapeutics Market
  • 7.5.3. France Protein Therapeutics Market
  • 7.5.4. Spain Protein Therapeutics Market
  • 7.5.5. Italy Protein Therapeutics Market
  • 7.5.6. Rest of Europe Protein Therapeutics Market
• 7.6. Asia-Pacific Protein Therapeutics Market Snapshot
  • 7.6.1. China Protein Therapeutics Market
  • 7.6.2. India Protein Therapeutics Market
  • 7.6.3. Japan Protein Therapeutics Market
  • 7.6.4. Australia Protein Therapeutics Market
  • 7.6.5. South Korea Protein Therapeutics Market
  • 7.6.6. Rest of Asia Pacific Protein Therapeutics Market
• 7.7. Latin America Protein Therapeutics Market Snapshot
  • 7.7.1. Brazil Protein Therapeutics Market
  • 7.7.2. Mexico Protein Therapeutics Market
• 7.8. Middle East & Africa Protein Therapeutics Market
  • 7.8.1. Saudi Arabia Protein Therapeutics Market
  • 7.8.2. South Africa Protein Therapeutics Market
  • 7.8.3. Rest of Middle East & Africa Protein Therapeutics Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Novo Nordisk AS
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Baxter International Inc.
  • 8.3.3. Amgen Inc.
  • 8.3.4. Merck and Co., Inc.
  • 8.3.5. Sanofi S.A.
  • 8.3.6. Eli Lilly And Company
  • 8.3.7. Abbott Laboratories
  • 8.3.8. Pfizer Inc.
  • 8.3.9. Johnson and Johnson (Janssen Pharmaceuticals)
  • 8.3.10. F. Hoffmann La Roche Ltd

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption